Article Text

Download PDFPDF

Research paper
Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy
  1. Arianna Tucci1,
  2. Yo-Tsen Liu1,2,3,4,
  3. Elisabeth Preza1,
  4. Robert D S Pitceathly1,2,
  5. Annapurna Chalasani5,
  6. Vincent Plagnol6,
  7. John M Land5,
  8. Daniah Trabzuni1,7,
  9. Mina Ryten1,
  10. on behalf of UKBEC,
  11. Zane Jaunmuktane8,
  12. Mary M Reilly1,2,
  13. Sebastian Brandner8,
  14. Iain Hargreaves5,
  15. John Hardy1,
  16. Andrew B Singleton9,
  17. Andrey Y Abramov1,
  18. Henry Houlden1,2
  1. 1Department of Molecular Neuroscience and Reta Lila Weston Research Laboratories, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
  2. 2MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
  3. 3Section of Epilepsy, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
  4. 4National Yang-Ming University School of Medicine, Taipei, Taiwan
  5. 5Neurometabolic unit, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, England
  6. 6UCL Genetics Institute (UGI), London, UK
  7. 7Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
  8. 8Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, London, UK
  9. 9Laboratory of Neurogenetics, National Institute of Aging, National Institutes of Health, Bethesda, Maryland, USA
  1. Correspondence to Dr Henry Houlden, Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK; h.houlden{at}ion.ucl.ac.uk

Abstract

Objective Charcot-Marie Tooth disease (CMT) forms a clinically and genetically heterogeneous group of disorders. Although a number of disease genes have been identified for CMT, the gene discovery for some complex form of CMT has lagged behind. The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but until now, mutations in the recessive forms of disease have never been identified.

Methods We here describe a family with three affected individuals who inherited in an autosomal recessive fashion a childhood onset neuropathy and optic atrophy. Using homozygosity mapping in the family and exome sequencing in two affected individuals we identified a novel protein-truncating mutation in the C12orf65 gene, which encodes for a protein involved in mitochondrial translation. Using a variety of methods we investigated the possibility of mitochondrial impairment in the patients cell lines.

Results We described a large consanguineous family with neuropathy and optic atrophy carrying a loss of function mutation in the C12orf65 gene. We report mitochondrial impairment in the patients cell lines, followed by multiple lines of evidence which include decrease of complex V activity and stability (blue native gel assay), decrease in mitochondrial respiration rate and reduction of mitochondrial membrane potential.

Conclusions This work describes a mutation in the C12orf65 gene that causes recessive form of CMT6 and confirms the role of mitochondrial dysfunction in this complex axonal neuropathy.

  • Genetics
  • Neuropathy

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.